Anti-inflammatory therapeutic drugs boost global sales

Over the past decade there is a growing confirmation that inflammation response is playing a crucial part in the pathogenesis of psychological anguish comprising of Schizophrenia, Psoriasis, Inflammatory Bowel diseases and respiratory diseases among many others. According to the ‘US News ‘Irritable Bowel Syndrome (IBS) affects nearly ten to fifteen percent of the Americans – nearly half of them are women – but sadly only five to seven percent of them get diagnosed for this distressing digestive problem. While studying the prevalence of arthritis in terms of age, race and gender CDC (Centres For Disease Control And Prevention) unveiled some shocking truth.

The study found out that those in the age group 18 to 44, 7.3 percent; 45 to 64, 30 percent and 65 and above, 49.7 percent fall under the diagnosed arthritis category. Owing to such facts the worldwide anti-inflammatory therapeutics segment is believed to see a CAGR of nearly 5.9 percent during the forecast period 2014 to 2020. Several industry experts hold anti-inflammatory biologics and NSAID responsible for the growth that are more focused, effective and have lesser side effects that conventional drugs.  And discerning this association would result in preventive measures in years to come, including susceptible patients to the areas with less awareness.

Thus speaking of a popular anti-inflammatory therapeutic treatment today, NSAID’s are prescribed to alleviate pain and lessen inflammation. By reason of its advantage to block the production of prostaglandins that’s associated with pain as well as inflammation the NSAID market has witnessed a great momentum. Pozen, Inc. a non-steroidal anti-inflammatory drugs recently saw its shares soar by 25.08 percent in the last week and up to 72.43 percent for the past four weeks. In another event Tiny Antibe Therapeutics made it known that it’s ready to shake up the booming NSAID industry and target $1.30, acquiring a remarkable 160 percent return. The sales of such drugs had topped approximately $12-billion by the end of 2010, dominated by household brands like Pfizer’s Celebrex and Novartis’s Voltaren. Oxford Pharmascience in a news on NSAID program uncovered its intention to focus on this $12billion market in 2015 and beyond. Iroko Pharmaceuticals beating the heat of competition has also zeroed in on its decision to include an ex NephroGenex, Inc. officer to enhance its commercialization initiatives.

Eyeing the bountiful prospects in the anti-inflammatory market, Allied Market Research has recently published a report titled “Global Anti-Inflammatory Therapeutics Market “. The report takes a closer look at the worldwide industry analysis, geography level analysis, demand, insight and forecast through 2014 to 2020. Another therapeutic segment making its mark in the anti-inflammation is the anti-inflammatory biologics. Amidst speculations that biologics improves results in rheumatoid arthritis, spondylitis, inflammatory bowel diseases and more has compelled it’s market to grow exponentially. Last week the Temple University made several heads turn by taking a lead in trial for latest COPD treatment. Temple is ready to test a drug YLP-001 that uses a biologic principle in order to target the loopholes in the existing treatment for COPD. In 2014 biologic drug Humara had recorded an incredible $6.3 billion and industry experts still remain assured about its growth. To top it all, the Vascular Biogenics Ltd. on Friday soared 9.08 percent making its way into the gainer list of the day. Competing shoulder to shoulder is Novartis whose biologic psoriasis drug has cleared phase 3 trial and is speeding towards an approval.

There is no doubt that anti-inflammatory therape utic drug manufacturers are busy filling new patients. Everyone in the aforesaid drug segment is committed to help the sufferers’ combat pain and obtain a significant market share from their existing and to be test drugs. 

View all reports related to Life Science Industry visit at:
https://www.alliedmarketresearch.com/life-sciences-market-report

 

Related Post